



Original Effective Date: 04/28/2022  
 Current Effective Date: 03/03/2023  
 Last P&T Approval/Version: 01/25/2023  
 Next Review Due By: 01/2024  
 Policy Number: C22822-A

## Pyrukynd (mitapivat)

### PRODUCTS AFFECTED

Pyrukynd (mitapivat)

### COVERAGE POLICY

*Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.*

*This Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide Molina Healthcare complete medical rationale when requesting any exceptions to these guidelines.*

#### **Documentation Requirements:**

*Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.*

#### **DIAGNOSIS:**

Pyruvate kinase (PK) deficiency

#### **REQUIRED MEDICAL INFORMATION:**

This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. If a drug within this policy receives an updated FDA label within the last 180 days, medical necessity for the member will be reviewed using the updated FDA label information along with state and federal requirements, benefit being administered and formulary preferencing. Coverage will be determined on a case-by case basis until the criteria can be updated through Molina Healthcare, Inc. clinical governance. Additional information may be required on a case-by-case basis to allow for adequate review.

#### **A. PYRUVATE KINASE (PK) DEFICIENCY**

1. Documentation of pyruvate kinase deficiency confirmed with genetic testing showing:

## Drug and Biologic Coverage Criteria

- a. Member has at least two mutant alleles in the PKLR (pyruvate kinase liver and red blood cell) gene, of which at least one is a missense mutation  
AND
  - b. Member is not homozygous for the R479H mutation  
AND
  - c. Member does not have two non-missense variants in the PKLR gene, without the presence of another missense variant  
AND
2. Documentation that in the previous 12 months, member has required at least 6 red blood cell transfusions  
AND
  3. Documentation that member's baseline hemoglobin is  $\leq 10$  mg/dL [DOCUMENTATION REQUIRED]  
AND
  4. Prescriber attests that member's medications have been reviewed and prescriber has not found any interactions or will appropriately monitor for adverse reactions and hemoglobin due to the interactions.  
**Note:** Use of Pyrukynd concomitantly with strong CYP3A inhibitors or inducers is not recommended. When used with a moderate CYP3A inhibitor, Pyrukynd dose should not exceed 20 mg twice daily.  
AND
  5. Prescriber attests that member will receive folic acid supplementation throughout treatment with requested therapy  
AND
  6. Prescriber attests that member does not have moderate or severe hepatic dysfunction

### CONTINUATION OF THERAPY:

#### A. PYRUVATE KINASE (PK) DEFICIENCY:

1. Adherence to therapy at least 85% of the time as verified by the prescriber or member medication fill history  
AND
2. Prescriber attests to or clinical reviewer has found no evidence of intolerable adverse effects or drug toxicity  
AND
3. Documentation of positive clinical response as demonstrated by an increase in hemoglobin  $\geq 1.5$  mg/dL from baseline and/or documented reduction in transfusion burden [DOCUMENTATION REQUIREMENT]  
AND
4. Prescriber attests that member's medications have been reviewed and prescriber has not found any interactions or will appropriately monitor for adverse reactions and hemoglobin due to the interactions.  
**Note:** Use of Pyrukynd concomitantly with strong CYP3A inhibitors or inducers is not recommended. When used with a moderate CYP3A inhibitor, Pyrukynd dose should not exceed 20 mg twice daily.

### DURATION OF APPROVAL:

Initial authorization: 6 months, Continuation of Therapy: 12 months

### PRESCRIBER REQUIREMENTS:

Prescribed by or in consultation with a board-certified hematologist.

If prescribed in consultation, consultation notes must be submitted with initial request and reauthorization requests.

## Drug and Biologic Coverage Criteria

### AGE RESTRICTIONS:

18 years of age or older

### QUANTITY:

One (1) 28-day pack per month

One Taper Pack, as needed for interruption in treatment or discontinuation

### Maximum Quantity Limits – 50 mg twice daily

[100 mg twice daily if Pyrukynd is used with a moderate CYP3A inducer and therapy with the inducer has no alternative]

### PLACE OF ADMINISTRATION:

The recommendation is that oral medications in this policy will be for pharmacy benefit coverage and patient self-administered.

## DRUG INFORMATION

### ROUTE OF ADMINISTRATION:

Oral

### DRUG CLASS:

Pyruvate Kinase Activators

### FDA-APPROVED USES:

Indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency

### COMPENDIAL APPROVED OFF-LABELED USES:

None

## APPENDIX

### Dose Titration Schedule for initiation of treatment with Pyrukynd:

Duration	Dosage
Week 1 through Week 4	5 mg twice daily
Week 5 through Week 8	If Hb is below normal range or patient has required a transfusion within the last 8 weeks: <ul style="list-style-type: none"><li>• Increase to 20 mg twice daily and maintain for 4 weeks.</li></ul> If Hb is within normal range and patient has not required a transfusion within the last 8 weeks: <ul style="list-style-type: none"><li>• Maintain 5 mg twice daily.</li></ul>
Week 9 through Week 12	If Hb is below normal range or patient has required a transfusion within the last 8 weeks: <ul style="list-style-type: none"><li>• Increase to 50 mg twice daily and maintain thereafter.</li></ul> If Hb is within normal range and patient has not required a transfusion within the last 8 weeks: <ul style="list-style-type: none"><li>• Maintain current dose (5 mg twice daily or 20 mg twice daily).</li></ul>
Maintenance	If Hb decreases, consider up-titration to the maximum of 50 mg twice daily as per the above schedule.

## BACKGROUND AND OTHER CONSIDERATIONS

### BACKGROUND:

Pyruvate kinase (PK) deficiency is a rare hereditary disorder which affects red blood cell (RBC) glycolysis. Pyruvate kinase catalyzes the final step in glycolysis, which is needed to produce adenosine triphosphate (ATP) in the red blood cell. Without ATP, the RBCs breakdown prematurely. Alterations in the PKLR gene are inherited in an autosomal recessive manner and result in a deficiency in the pyruvate kinase enzyme. Due to this deficiency RBCs last days to weeks, rather than the typical average of 120 days. This results in a lifelong, chronic hemolytic anemia. The estimated disease prevalence is 1 per 20,000 in the Caucasian population. There is a higher prevalence in the Pennsylvania Amish community due to the founder effect.

The signs and symptoms of pyruvate kinase deficiency can include anemia, fatigue, exercise intolerance, jaundice, memory loss, and difficulty concentrating. Additional complications are also observed in individuals with PK deficiency, including iron overload, gallstones, bone fracture/osteoporosis, and spleen enlargement. Management of PK deficiency is supportive and includes RBC transfusions, splenectomy, cholecystectomy, and iron chelation therapy.

Pyrukynd (mitapivat) is an oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat binds to and activate the PK enzyme, increasing ATP production in the RBC. Mitapivat was studied in two clinical trials: ACTIVATE (NCT03548220) and ACTIVATE-T (NCT03559699). ACTIVATE was a phase 3, randomized, double-blind placebo-controlled trial in 80 patients with pyruvate kinase deficiency (PKD), who were not regularly receiving blood transfusion. The study was divided into two segments. The first was a dose optimization period in which the dose was started at 5 mg twice daily followed by sequential dose increases to 20 mg twice daily and 50 mg twice daily, depending upon tolerance. The second part was a fixed dose period, in which the participants received their optimized dose. Participants were 18 years and older, with a confirmed diagnosis of PKD documented by the presence of at least 2 mutant alleles in the PKLR gene, of which at least 1 is a missense mutation. Participants were excluded if they were homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene. Baseline hemoglobin concentration for all participants was requires to be less than or equal to 10.0 g/dL regardless of gender. Participants could have received no more than 4 transfusions in the 12 months prior to the study and no transfusion sin the 3 months prior to the study. Hemoglobin response was defined as a  $\geq 1.5$  g/dL increase in Hb from baseline sustained at two or more scheduled assessments (Weeks 16, 20, and 24) during the fixed-dose period without transfusions. Hemoglobin response was achieved in 16 participants (40%, n=40) in the Pyrukynd group and 0 participants in the placebo group (n=40), which was a statistically significant difference ( $p < 0.0001$ ). ACTIVATE-T evaluated the efficacy of mitapivant in participants that received regular transfusions. This trial was a multinational single arm trial in 27 adults with PKD. Participants were required to have received a minimum of 6 transfusion episodes in the 52- week period prior to study consent. Participants were required to have a confirmed diagnosis of PKD documented by the presence of at least 2 mutant alleles in the PKLR gene, of which at least 1 is a missense mutation. Participants were excluded if they were homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene. Participants (n=27) had a median of 9 transfusion episodes prior to the study, with a median of 7 RBC units transfused standardized to 24 weeks. Efficacy was defined as a  $\geq 33\%$  reduction in RBC units transfused during the study period compared to the participants baseline. Nine participants (33%) achieved the defined transfusion response (95% CI 17,54) and six participants (22%) were transfusion free (95% CI 9, 42).

In the ACTIVATE trial, the most In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities ( $\geq 10\%$ ) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia. The adverse reactions reported in the population of patients who were regularly transfused (ACTIVATE-T) were consistent with that seen in ACTIVATE.

**CONTRAINDICATIONS/EXCLUSIONS/DISCONTINUATION:**

All other uses of Pyrukynd (mitapivat) are considered experimental/investigational and therefore, will follow Molina’s Off- Label policy. Contraindications to Pyrukynd (mitapivat) include: concomitant use with strong CYP3A inhibitors and inducers, concomitant use with sensitive CYP3A, CYP2B6, CYP2C substrates including hormonal contraceptives, that have a narrow therapeutic index, patients with moderate or severe hepatic impairment.

**OTHER SPECIAL CONSIDERATIONS:**

Pyrukynd (mitapivat) is taken with or without food and is swallowed whole. Tablets are not to be split, crushed, chewed, or dissolved. Blister wallets should be stored in the original carton until use.

Pyrukynd (mitapivat) should be started at 5 mg twice daily for the first 4 weeks. The dose may then be increased to 20 mg twice daily for the next 4 weeks (weeks 5 through 8), if the member’s hemoglobin is below normal or the member has required a transfusion within the last 8 weeks. The dose may be increased to 50 mg twice daily (maximum dose), if the member’s hemoglobin is below normal or the member has required a transfusion within the last 8 weeks. If the member achieves a hemoglobin above more and has not required a transfusion in the previous 8 weeks, the current dose (5 mg, 20 mg or 50 mg twice daily) should be maintained.

To avoid the risk of acute hemolysis, Pyrukynd (mitapivat) should not be abruptly interrupted or discontinued. The dose should be tapered over 7 to 14 days, dependent upon the current dose.

Dose Taper Schedule:

Current Dose	Day 1-7	Day 8-14	Day 15
5 mg twice daily	5 mg once daily	Discontinue	
20 mg twice daily	20 mg once daily	5 mg once daily	Discontinue
50 mg twice daily	50 mg once daily	20 mg once daily	Discontinue

Special Populations:

Safety and efficacy of Pyrukynd (mitapivat) has not been established in pediatric patients. Mitapivat undergoes extensive hepatic metabolism. Moderate and severe hepatic impairment is expected to increase the systemic exposure, therefore use should be avoided in this population.

**CODING/BILLING INFORMATION**

*Note: 1) This list of codes may not be all-inclusive. 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement*

HCPCS CODE	DESCRIPTION
NA	

**AVAILABLE DOSAGE FORMS:**

- Pyrukynd TABS 5MG
- Pyrukynd TABS 20MG
- Pyrukynd TABS 50MG
- Pyrukynd Taper Pack TBPK 5MG
- Pyrukynd Taper Pack TBPK 7 x 20 MG & 7 x 5 MG
- Pyrukynd Taper Pack TBPK 7 x 50 MG & 7 x 20 MG

**REFERENCES**

1. Pyrukynd (mitapivat) tablet [prescribing information], Cambridge, MA: Agios Pharmaceuticals, Inc., February 2022.
2. Boscoe, A. N., Yan, Y., Hedgeman, E., van Beers, E. J., Al-Samkari, H., Barcellini, W., Eber, S. W., Glader, B., Yaish, H. M., Chonat, S., Sharma, M., Kuo, K., Neufeld, E. J., Wang, H., Verhovsek, M., Sheth, S., & Grace, R. F. (2021). Comorbidities and complications in adults with pyruvate kinase deficiency. *European journal of haematology*, 106(4), 484–492. <https://doi.org/10.1111/ejh.13572>
3. Boscoe AN, et al. Comorbidities and complications in adults with pyruvate kinase deficiency. *Eur J Haematol*. 2021;106(4):484-492. doi:10.1111/ejh.13572
4. Pyruvate Kinase Deficiency - NORD (National Organization for Rare Disorders). (2022). Retrieved 28 March 2022, from <https://rarediseases.org/rare-diseases/pyruvate-kinase-deficiency/>

SUMMARY OF REVIEW/REVISIONS	DATE
REVISION- Notable revisions: Required Medical Information Continuation of Therapy Contraindications/Exclusions/Discontinuation	Q1 2023
INITIAL REVIEW COMPLETED	Q2 2022